Concepedia

Charlotte McKee

CM

Statistics

Publications

21

Citations

8.2K

H-Index

16

Active since

1985

Affiliations

Vertex Pharmaceuticals (United States)(Current)

National Jewish Health

University of Alabama at Birmingham

University of Colorado Denver

German Center for Lung Research

Charlotte McKee is an author at Vertex Pharmaceuticals (United States) specializing in life sciences, cystic fibrosis, and cftr gene mutations.

Publications per year

1985–2019

21

Publications

21

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

Peter G. Middleton, Marcus Mall, Pavel Dřevı́nek et al. · New England Journal of Medicine · 2019 · 2.1K citations · Full text

, , +16

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Harry Heijerman, Edward F. McKone, D.G. Downey et al. · The Lancet · 2019 · 1.4K citations · Full text

, , +14

Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44.

Charlotte McKee, Margaret B. Penno, Mary K. Cowman et al. · Journal of Clinical Investigation · 1996 · 807 citations · Full text

, , +17

Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del

Jennifer L. Taylor‐Cousar, À. Munck, Edward F. McKone et al. · New England Journal of Medicine · 2017 · 778 citations · Full text

, , +10

VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

D. Keating, Gautham Marigowda, Lucy Burr et al. · New England Journal of Medicine · 2018 · 727 citations · Full text

, , +13

1–5 of 21